Gene replacement strategies for lung cancer

J. A. Roth, T. Mukhopadhyay, W. W. Zhang, Toshiyoshi Fujiwara, R. Georges

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Advances in our understanding of the molecular genetics of cancer present an opportunity to develop prevention and treatment strategies based on the reversal of specific genetic lesions. This strategy is analogous to the classic concept of gene therapy for replacement of defective or nonfunctioning genes. The gene families implicated in carcinogenesis include dominant oncogenes and tumor suppressor genes. Regional administration of viral vectors expressing wildtype p53 and antisense K-ras prevents tumor growth for tumors with the specific genetic lesions in orthotopic tumor models and mediates regression of large established tumors. These studies provide a rationale for a new clinical protocol recently approved by the National Institutes of Health Recombinant DNA Advisory Committee and Food and Drug Administration to replace a defective p53 gene with intratumor injection of recombinant retrovirus expressing wild-type p53 or elimination of activated K-ras by expression of antisense K-ras messenger RNA. If these agents are efficacious, their lack of toxicity may provide a sufficiently high therapeutic index such that they could be used as an adjuvant to surgery to treat patients with earlier stages of cancer or as prevention for second primary cancers for individuals with genetic abnormalities in premalignant lesions. Although much research needs to be done, the possibility of specific gene targeting with a high therapeutic index makes this a promising area of investigation.

Original languageEnglish
Pages (from-to)105-109
Number of pages5
JournalSeminars in Radiation Oncology
Volume6
Issue number2
DOIs
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

genes
lungs
Lung Neoplasms
tumors
cancer
lesions
Genes
Neoplasms
tumor suppressor genes
oncogenes
ribonucleic acids
gene therapy
abnormalities
surgery
toxicity
health
regression analysis
elimination
Second Primary Neoplasms
Recombinant DNA

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Cite this

Gene replacement strategies for lung cancer. / Roth, J. A.; Mukhopadhyay, T.; Zhang, W. W.; Fujiwara, Toshiyoshi; Georges, R.

In: Seminars in Radiation Oncology, Vol. 6, No. 2, 1996, p. 105-109.

Research output: Contribution to journalArticle

Roth, JA, Mukhopadhyay, T, Zhang, WW, Fujiwara, T & Georges, R 1996, 'Gene replacement strategies for lung cancer', Seminars in Radiation Oncology, vol. 6, no. 2, pp. 105-109. https://doi.org/10.1016/S1053-4296(96)80007-5
Roth, J. A. ; Mukhopadhyay, T. ; Zhang, W. W. ; Fujiwara, Toshiyoshi ; Georges, R. / Gene replacement strategies for lung cancer. In: Seminars in Radiation Oncology. 1996 ; Vol. 6, No. 2. pp. 105-109.
@article{f3be5a6dc8144a2890b46429b03fe126,
title = "Gene replacement strategies for lung cancer",
abstract = "Advances in our understanding of the molecular genetics of cancer present an opportunity to develop prevention and treatment strategies based on the reversal of specific genetic lesions. This strategy is analogous to the classic concept of gene therapy for replacement of defective or nonfunctioning genes. The gene families implicated in carcinogenesis include dominant oncogenes and tumor suppressor genes. Regional administration of viral vectors expressing wildtype p53 and antisense K-ras prevents tumor growth for tumors with the specific genetic lesions in orthotopic tumor models and mediates regression of large established tumors. These studies provide a rationale for a new clinical protocol recently approved by the National Institutes of Health Recombinant DNA Advisory Committee and Food and Drug Administration to replace a defective p53 gene with intratumor injection of recombinant retrovirus expressing wild-type p53 or elimination of activated K-ras by expression of antisense K-ras messenger RNA. If these agents are efficacious, their lack of toxicity may provide a sufficiently high therapeutic index such that they could be used as an adjuvant to surgery to treat patients with earlier stages of cancer or as prevention for second primary cancers for individuals with genetic abnormalities in premalignant lesions. Although much research needs to be done, the possibility of specific gene targeting with a high therapeutic index makes this a promising area of investigation.",
author = "Roth, {J. A.} and T. Mukhopadhyay and Zhang, {W. W.} and Toshiyoshi Fujiwara and R. Georges",
year = "1996",
doi = "10.1016/S1053-4296(96)80007-5",
language = "English",
volume = "6",
pages = "105--109",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Gene replacement strategies for lung cancer

AU - Roth, J. A.

AU - Mukhopadhyay, T.

AU - Zhang, W. W.

AU - Fujiwara, Toshiyoshi

AU - Georges, R.

PY - 1996

Y1 - 1996

N2 - Advances in our understanding of the molecular genetics of cancer present an opportunity to develop prevention and treatment strategies based on the reversal of specific genetic lesions. This strategy is analogous to the classic concept of gene therapy for replacement of defective or nonfunctioning genes. The gene families implicated in carcinogenesis include dominant oncogenes and tumor suppressor genes. Regional administration of viral vectors expressing wildtype p53 and antisense K-ras prevents tumor growth for tumors with the specific genetic lesions in orthotopic tumor models and mediates regression of large established tumors. These studies provide a rationale for a new clinical protocol recently approved by the National Institutes of Health Recombinant DNA Advisory Committee and Food and Drug Administration to replace a defective p53 gene with intratumor injection of recombinant retrovirus expressing wild-type p53 or elimination of activated K-ras by expression of antisense K-ras messenger RNA. If these agents are efficacious, their lack of toxicity may provide a sufficiently high therapeutic index such that they could be used as an adjuvant to surgery to treat patients with earlier stages of cancer or as prevention for second primary cancers for individuals with genetic abnormalities in premalignant lesions. Although much research needs to be done, the possibility of specific gene targeting with a high therapeutic index makes this a promising area of investigation.

AB - Advances in our understanding of the molecular genetics of cancer present an opportunity to develop prevention and treatment strategies based on the reversal of specific genetic lesions. This strategy is analogous to the classic concept of gene therapy for replacement of defective or nonfunctioning genes. The gene families implicated in carcinogenesis include dominant oncogenes and tumor suppressor genes. Regional administration of viral vectors expressing wildtype p53 and antisense K-ras prevents tumor growth for tumors with the specific genetic lesions in orthotopic tumor models and mediates regression of large established tumors. These studies provide a rationale for a new clinical protocol recently approved by the National Institutes of Health Recombinant DNA Advisory Committee and Food and Drug Administration to replace a defective p53 gene with intratumor injection of recombinant retrovirus expressing wild-type p53 or elimination of activated K-ras by expression of antisense K-ras messenger RNA. If these agents are efficacious, their lack of toxicity may provide a sufficiently high therapeutic index such that they could be used as an adjuvant to surgery to treat patients with earlier stages of cancer or as prevention for second primary cancers for individuals with genetic abnormalities in premalignant lesions. Although much research needs to be done, the possibility of specific gene targeting with a high therapeutic index makes this a promising area of investigation.

UR - http://www.scopus.com/inward/record.url?scp=0030000528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030000528&partnerID=8YFLogxK

U2 - 10.1016/S1053-4296(96)80007-5

DO - 10.1016/S1053-4296(96)80007-5

M3 - Article

AN - SCOPUS:0030000528

VL - 6

SP - 105

EP - 109

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 2

ER -